EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudieOpen Access · CC BY-NC-ND 4.0

Integrating baseline ctDNA-derived tumor metrics enhances risk stratification in HR-positive/HER2-negative advanced breast cancer: a real-world multicenter cohort study from Austria

N Dobrić, S O Hasenleithner, C Suppan, E V Klocker, D Hlauschek, R Graf, C Beichler, C Albertini, D Egle, D Liu, A M Starzer, R Bartsch und 6 weitere

ESMO Open · 2026-04 · 11 (4) · 106939

DOI: 10.1016/j.esmoop.2026.106939 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift ESMO Open, 2026-04. Verfasst von N Dobrić und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria. Hauptthemen laut MEDLINE: Breast Neoplasms, Circulating Tumor DNA, Biomarkers, Tumor. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AstraZeneca PLC, Christian Doppler Research Association, Novartis AG.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Advances in endocrine therapies for hormone receptor (HR)-positive/HER2-negative advanced breast cancer (ABC) continue to transform care and significantly improve patient outcomes. However, the integration of molecular and clinical risk stratification into guiding individualized treatment selection remains a key challenge. We therefore evaluated whether the integration of baseline circulating tumor DNA (ctDNA)-derived tumor metrics enhances risk stratification among patients receiving early lines of treatment of HR-positive ABC in a real-world multicenter cohort of patients in Austria. METHODS: Patients with HR-positive/HER2-negative ABC treated at multiple Austrian centers were included. CtDNA was analyzed using a 77-gene panel (AVENIO ctDNA Expanded Kit). Tumor fraction (TFx) was estimated via two complementary approaches: untargeted aneuploidy assessment using mFAST-SeqS, and the highest variant allele frequency (hVAF) from the AVENIO assay. Somatic variants and single, binary, and three-level composite TFx metrics were assessed for their association with progression-free and overall survival (PFS, OS). RESULTS: We analyzed 225 ctDNA samples from 184 patients [128 before first-line (1L) and 76 before second-line (2L) treatment], including 40 paired samples. Overall TFx was low (median z-score 2.49; range -0.5-208.3), with higher levels in 2L, although the difference did not reach statistical significance (P = 0.058). In contrast, the hVAF was significantly higher in the 2L cohort (P = 0.007). Somatic variant burden was significantly increased in 2L (P < 0.001), with notably more frequent ESR1 mutations (26.7% versus 7.1% in 1L). Median PFS was 29.2 months in 1L and 6.0 months in 2L, while median OS was 57.3 months and 16.1 months, respectively. TP53 and ESR1 mutations, and all ctDNA-based metrics were significantly associated with PFS and OS, with a three-level composite ctDNA variable showing the highest prognostic discrimination. CONCLUSIONS: Our findings demonstrate that integrating baseline ctDNA-derived TFx metrics with established clinical variables significantly improves risk stratification in HR-positive/HER2-negative ABC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsCirculating Tumor DNABiomarkers, TumorHumansFemaleAustriaErb-b2 Receptor Tyrosine KinasesRisk AssessmentCohort StudiesMiddle AgedAgedAdultReceptors, Progesterone

Stichwörter der Autor:innen

HR-positive/HER2-negative breast cancerctDNAliquid biopsymetastatic breast cancernext-generation sequencingprecision medicine

Substanzen

Circulating Tumor DNAErb-b2 Receptor Tyrosine KinasesBiomarkers, TumorERBB2 protein, humanReceptors, Progesterone

Autor:innen und Institutionen

  • Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
  • Institute of Human Genetics, Diagnostic and Research Center for Molecular Biomedicine, Medical University of Graz, Graz, Austria.
  • Department of Gynecology, Breast Cancer Center Tirol, Medical University of Innsbruck, Innsbruck, Austria.
  • School of Medicine, Tsinghua Medicine, Tsinghua University, Beijing, China; Division of Oncology, Hillmans Cancer Center, University of Pittsburgh, Pittsburgh, USA.
  • Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
  • Institute of Human Genetics, Diagnostic and Research Center for Molecular Biomedicine, Medical University of Graz, Graz, Austria; Christian Doppler Laboratory for Liquid Biopsies for Early Detection of Cancer, Graz, Aus…

Förderung

  • AstraZeneca PLC
  • Christian Doppler Research Association
  • Novartis AG
  • Daiichi Sankyo Chemical Pharma Co Ltd
  • Pfizer Inc

Zitieren

APA

Dobrić, N., Hasenleithner, S. O., Suppan, C., Klocker, E. V., Hlauschek, D., Graf, R., Beichler, C., Albertini, C., Egle, D., Liu, D., Starzer, A. M., Bartsch, R., Moser, T., Rinnerthaler, G., Jost, P. J., Heitzer, E., Dandachi, N., & Balic, M. (2026). Integrating baseline ctDNA-derived tumor metrics enhances risk stratification in HR-positive/HER2-negative advanced breast cancer: a real-world multicenter cohort study from Austria. ESMO Open, 11(4), 106939. https://doi.org/10.1016/j.esmoop.2026.106939

Vancouver

Dobrić N, Hasenleithner SO, Suppan C, Klocker EV, Hlauschek D, Graf R, et al. Integrating baseline ctDNA-derived tumor metrics enhances risk stratification in HR-positive/HER2-negative advanced breast cancer: a real-world multicenter cohort study from Austria. ESMO Open. 2026;11(4):106939. doi:10.1016/j.esmoop.2026.106939

BibTeX
@article{Dobri2026,
  author = {Dobrić, N and Hasenleithner, S O and Suppan, C and Klocker, E V and Hlauschek, D and Graf, R and Beichler, C and Albertini, C and Egle, D and Liu, D and Starzer, A M and Bartsch, R and Moser, T and Rinnerthaler, G and Jost, P J and Heitzer, E and Dandachi, N and Balic, M},
  title = {Integrating baseline ctDNA-derived tumor metrics enhances risk stratification in HR-positive/HER2-negative advanced breast cancer: a real-world multicenter cohort study from Austria},
  journal = {ESMO Open},
  year = {2026},
  volume = {11},
  number = {4},
  pages = {106939},
  doi = {10.1016/j.esmoop.2026.106939}
}
Kostenlos starten →